Stage 1 Kidney Disease: What It Means

A Stage 1 chronic kidney disease diagnosis often catches people completely off guard — because their kidney test results look almost entirely normal. The eGFR number on the lab report is 90 or above, which falls within the normal range. Blood creatinine is unremarkable. Yet the diagnosis stands. Stage 1 CKD is not a disease of failing filtration; it is a disease of early structural or functional damage to the kidneys with filtration still preserved. The damage marker — usually detectable protein in the urine or an abnormal finding on imaging — is what creates the diagnosis. Understanding this distinction is the foundation for understanding what Stage 1 kidney disease actually means and what can be done about it.

The good news is that Stage 1 is the earliest possible stage of CKD, which means it is also the stage with the greatest opportunity to slow or halt progression. Treatments that work at this stage — blood pressure control, specific medications, and lifestyle changes — are proven to preserve kidney function for years or even decades when applied consistently. The challenge is that Stage 1 CKD is identified entirely through laboratory testing, not through symptoms, which means it is found only in people who are screened. Knowing your numbers is the first step toward making meaningful changes that protect your kidneys for the long term.

What Stage 1 Kidney Disease Actually Means

Stage 1 CKD (formally called Stage G1 in the KDIGO classification system) is defined by two criteria: an estimated glomerular filtration rate (eGFR) of 90 ml/min/1.73m² or above, and the presence of at least one marker of kidney damage that has persisted for more than 3 months. The eGFR is calculated from serum creatinine using the CKD-EPI 2021 formula, which accounts for age and sex. An eGFR of 90 or above means the kidneys are filtering blood at a normal rate — the filtration machinery is intact. More on what this number means in context is in our guide to kidney function tests.

The damage marker is the critical element that separates a G1 CKD diagnosis from a normal result. The most common damage marker is albuminuria — the presence of the protein albumin in the urine at levels above 30 mg per gram of creatinine (the A2 or A3 category on the urine ACR test). Other accepted damage markers include microscopic hematuria with RBC casts in the urine (indicating glomerular bleeding), structural abnormalities on kidney imaging such as polycystic kidneys or reflux nephropathy, pathological findings on kidney biopsy, or a history of kidney transplant. Without a damage marker, an eGFR of 90 or above is simply normal kidney function — not Stage 1 CKD. This is an important distinction that prevents over-diagnosis in people who simply have healthy kidneys.

The three-month duration requirement distinguishes CKD from acute kidney injury (AKI). A single elevated urine protein result or one low eGFR reading from an illness does not establish chronic kidney disease — the abnormality must be present and documented across at least two measurements separated by 3 months. The complete staging system and how G1 fits within the broader CKD classification is covered in our guide to chronic kidney disease stages.

Who Gets Diagnosed with Stage 1 CKD

Stage 1 CKD is found almost exclusively through screening in high-risk populations. The patients who receive this diagnosis most commonly include the following groups.

People with early diabetic nephropathy. After 5 to 10 years of type 2 diabetes with suboptimal glucose or blood pressure control, microalbuminuria (a urine ACR of 30 to 300 mg/g) typically appears while eGFR remains entirely normal. This is the classic G1 presentation: the filtration machinery is still working, but the glomerular capillary walls are beginning to leak albumin — a sign that the delicate filtering units are under stress. In type 1 diabetes, a similar trajectory occurs typically after 10 to 15 years of disease. Annual urine ACR testing in all diabetic patients exists precisely to detect this early, when intervention is most effective.

People with IgA nephropathy. IgA nephropathy is the most common primary glomerulonephritis worldwide and most frequently presents in young adults in their 20s and 30s. The clinical picture is typically microscopic hematuria — blood in the urine detectable on a dipstick or urinalysis but not visible to the naked eye — often combined with low-level proteinuria. When both hematuria and proteinuria persist for more than 3 months in the context of a normal or near-normal eGFR, a Stage G1 diagnosis of CKD is established, usually confirmed by kidney biopsy. Biopsy findings (the Oxford MEST-C score) predict long-term progression more accurately than eGFR or proteinuria alone at this early stage.

People with autosomal dominant polycystic kidney disease (ADPKD). ADPKD is the most common inherited kidney disease, affecting approximately 1 in 400 to 1 in 1,000 people. The kidneys develop multiple fluid-filled cysts that grow progressively over decades. In young adults with ADPKD, eGFR remains at G1 level (90 or above) well into the 30s or even early 40s while cysts are readily detectable on ultrasound or MRI. The diagnosis is established by imaging and sometimes genetic testing (PKD1 or PKD2 gene mutations). Annual kidney volume measurement by MRI is more predictive of progression trajectory than eGFR alone, which is why the Mayo Clinic imaging classification (1A through 1E based on kidney volume) is used alongside eGFR staging in ADPKD.

People with lupus nephritis. Systemic lupus erythematosus (SLE) frequently involves the kidneys, and lupus nephritis can present at any class (I through V based on WHO/ISN pathological classification). At Stage G1 eGFR, lupus nephritis may present with active urinary sediment — RBC casts, granular casts — that serve as damage markers even with preserved filtration. Kidney biopsy is required to classify lupus nephritis and guide treatment with mycophenolate mofetil, corticosteroids, and newer agents such as belimumab and voclosporin.

Kidney transplant recipients. By convention, all kidney transplant recipients are classified as having CKD because a transplanted kidney carries inherent structural damage from the donor-to-recipient process and long-term immunosuppression. Even a transplant recipient with an eGFR of 90 who feels perfectly well carries a CKD G1 classification. Monitoring in transplant recipients involves regular eGFR, urine ACR, tacrolimus levels, and protocol biopsies as specified by the transplant center.

Why There Are No Symptoms at Stage 1

The kidneys possess enormous functional reserve — so large that roughly 75 percent of filtering capacity must be lost before the body begins to experience the consequences of impaired kidney function. At Stage G1, filtration rate is at or above 90 percent of normal. The kidneys are filtering waste efficiently, maintaining electrolyte balance, regulating blood volume, and producing erythropoietin and vitamin D at adequate levels. None of the metabolic disruptions that cause kidney disease symptoms — fluid retention, elevated creatinine causing fatigue, potassium accumulation, or acid build-up — are occurring at this stage.

What is happening is damage at the microscopic level — leaky glomerular capillaries allowing protein to escape into the urine, cysts growing silently within the kidney parenchyma, or inflammatory cells infiltrating the glomeruli — that produces no sensation whatsoever. This is both reassuring (the kidneys are still working well) and challenging (there is no warning signal to prompt the patient to seek care). The only way to find Stage 1 CKD is through systematic screening. Current guidelines recommend annual urine ACR and serum creatinine (for eGFR calculation) in all adults with diabetes and in all adults with hypertension.

How Stage 1 Is Monitored

At Stage G1, the monitoring interval is annual — once per year — for patients who are stable. A stable G1 patient is one whose eGFR remains at 90 or above, whose urine ACR is not worsening, and whose blood pressure is controlled. The monitoring panel includes serum creatinine (to calculate eGFR), urine ACR, and blood pressure measurement at every visit. In diabetic patients, HbA1c is checked every 3 to 6 months as part of routine diabetes management.

A concerning trend at G1 is an eGFR that is declining at more than 2 to 3 ml/min per year, or a urine ACR that is increasing from A2 toward A3 despite treatment. Either finding warrants accelerating monitoring to every 6 months and reassessing medication adjustments. An acute illness, a new nephrotoxic medication (particularly NSAIDs or certain antibiotics), or poorly controlled blood pressure are the most common reversible reasons for an unexpected eGFR dip within the G1 range. A single low eGFR reading during an acute illness does not represent CKD progression — it needs to be rechecked after recovery. More on the tests used to track kidney health over time is in our guide to how doctors diagnose kidney disease.

Treatment Goals at Stage 1

Treatment at Stage G1 is entirely focused on slowing progression and reducing cardiovascular risk. The kidneys themselves do not require any direct supportive measures at this stage — there is no anemia to treat, no bicarbonate to supplement, no phosphate to restrict. The interventions are all about protecting the kidneys and the cardiovascular system from further damage.

Blood pressure control to below 130/80 mmHg is the most important modifiable intervention at every stage of CKD, including G1. In patients with proteinuric CKD, an ACE inhibitor (such as lisinopril, ramipril, or enalapril) or an ARB (such as losartan, valsartan, or irbesartan) is the preferred antihypertensive because these agents reduce intraglomerular pressure and proteinuria beyond their blood pressure-lowering effect — a mechanism-specific benefit that other antihypertensives do not share. ACE inhibitors and ARBs should not be combined (dual RAAS blockade), as the ONTARGET trial demonstrated this combination increases acute kidney injury and hyperkalemia risk without providing additional kidney protection.

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) are now recommended by KDIGO 2024 for CKD patients with a urine ACR of 200 mg/g or above at any eGFR from 25 upward, regardless of whether diabetes is present. The DAPA-CKD and EMPA-KIDNEY trials demonstrated that SGLT2 inhibitors reduce the composite risk of eGFR halving, kidney failure, and cardiovascular death even in non-diabetic CKD patients. In patients with type 2 diabetes and CKD, the FLOW trial (2024) established GLP-1 receptor agonists as an additional kidney-protective agent, reducing kidney failure events by approximately 24 percent.

Lifestyle modifications that contribute meaningfully at Stage G1 include dietary sodium restriction to below 2 grams per day (which reduces both blood pressure and proteinuria), weight management (obesity causes glomerular hyperfiltration that accelerates proteinuria), regular aerobic exercise (150 minutes or more per week of moderate-intensity activity), and smoking cessation (smoking is an independent risk factor for CKD progression and cardiovascular disease).

What Stage 1 Prognosis Depends On

Two patients with Stage G1 CKD can have very different 10- and 20-year outlooks, and the difference is driven by three factors: the urine albumin level, the underlying diagnosis, and how well treatment controls both.

The urine albumin level at G1 is the strongest predictor of long-term outcome. According to the KDIGO heat map, a G1 patient with A1 albuminuria (ACR below 30 mg/g) is in the low-risk category — near-normal kidney prognosis. A G1 patient with A3 albuminuria (ACR above 300 mg/g) is already in the high-risk category — the same risk tier as a patient with Stage G3a eGFR but low albuminuria. This means that a patient with a preserved eGFR of 90 but heavy proteinuria faces a significantly worse long-term outlook than a patient with an eGFR of 48 and no proteinuria.

The underlying diagnosis shapes trajectory and treatment response. Diabetic nephropathy that is caught at microalbuminuria (ACR 30 to 300 mg/g, G1) and treated aggressively with RAAS blockade, SGLT2 inhibitors, and tight glucose control can be stabilized or even partially reversed — some patients achieve a return to A1 albumin levels. ADPKD follows a predictable trajectory determined by kidney volume growth rates; tolvaptan can slow that growth in high-risk patients. IgA nephropathy with low-risk biopsy findings often remains stable for decades; high-risk biopsy findings require more aggressive treatment. Questions to bring to your nephrologist about prognosis and treatment targets are covered in our guide to questions to ask during a kidney checkup.

When to See a Nephrologist at Stage 1

Many patients with Stage G1 CKD are managed entirely in primary care. However, nephrology referral is appropriate in specific situations. Proteinuria in the nephrotic range (urine ACR above 3,000 mg/g or 24-hour protein above 3.5 grams) requires nephrology evaluation, as this level of protein loss indicates severe glomerular disease. Hematuria combined with proteinuria raises the possibility of an underlying glomerulonephritis (IgA nephropathy, thin basement membrane disease, ANCA vasculitis) that may require kidney biopsy for diagnosis. Any eGFR decline of more than 3 to 5 ml/min per year despite optimized treatment warrants nephrology review. Suspected or confirmed ADPKD with Class 1C–1E imaging pattern is a candidate for tolvaptan, which is prescribed and monitored by nephrologists. Systemic diseases with kidney involvement — lupus, vasculitis, amyloidosis — require multidisciplinary care including nephrology. When in doubt about the cause of the damage marker or the appropriate treatment intensity, early nephrology consultation is almost always the right answer. A review of annual monitoring parameters is covered in our guide to the annual kidney health checklist.

Frequently Asked Questions

Can Stage 1 CKD be reversed? In some cases, yes — particularly when the damage marker is albuminuria related to an addressable cause. Patients with early diabetic nephropathy (microalbuminuria at G1) who achieve tight glucose control, optimal blood pressure, and SGLT2 inhibitor therapy sometimes see their urine ACR normalize back to A1 levels. For structural damage causes — polycystic kidneys, reflux nephropathy, post-transplant — the underlying structural change is permanent, though progression can be slowed. The more accurate framing for most patients is “stabilizable” rather than “reversible” — the goal is preventing further damage, not expecting that existing damage will disappear.

How serious is Stage 1 kidney disease? Stage 1 CKD is the earliest stage of kidney disease, and most patients with well-managed G1 CKD do not progress to kidney failure during their lifetimes. The primary risk at this stage is cardiovascular — CKD at every stage independently increases the risk of heart attack and stroke, and this cardiovascular risk is particularly important at G1 because most patients have a coexisting condition (diabetes, hypertension) that also raises cardiovascular risk. The seriousness of a G1 diagnosis depends heavily on the urine albumin level and the underlying cause. A G1 patient with A3 albuminuria has a more serious prognosis than one with A1. Taking the diagnosis seriously — adhering to treatment, attending monitoring appointments, and making lifestyle changes — is the most effective response.

How long can you stay at Stage 1? Many patients with Stage G1 CKD remain at G1 for their entire lives, particularly those whose damage marker is successfully treated. In diabetic nephropathy treated with RAAS blockade and SGLT2 inhibitors, the annual eGFR decline can be slowed to near zero, and some patients remain at G1 indefinitely. In ADPKD, progression to lower eGFR stages typically occurs over 20 to 30 years. IgA nephropathy with low-risk biopsy findings may remain stable for decades. Conversely, high-risk G1 patients — those with nephrotic-range proteinuria, rapidly enlarging polycystic kidneys, or poorly controlled diabetes and hypertension — may progress to G2 or G3 within 5 to 10 years without intervention.

Medications to Avoid at Stage 1 CKD

Even at Stage G1, when kidneys are filtering at a normal rate, certain medications can accelerate kidney damage or cause acute kidney injury that pushes eGFR downward. The most important class to avoid is non-steroidal anti-inflammatory drugs (NSAIDs): ibuprofen, naproxen, diclofenac, and celecoxib. NSAIDs inhibit the prostaglandins that maintain glomerular blood flow by dilating the afferent arteriole. In a person with CKD — even mild CKD — this prostaglandin-dependent dilation is more important for maintaining filtration than in a person with normal kidneys. Regular NSAID use in a G1 patient can cause a measurable drop in eGFR and accelerate proteinuria. Occasional use for acute pain is lower risk, but any regular or prolonged use should be discussed with the prescribing doctor.

Contrast agents used in CT scanning (iodinated contrast media) carry a risk of contrast-induced nephropathy in patients with pre-existing kidney disease. At Stage G1, this risk is low but not zero, particularly in patients who are dehydrated or also taking nephrotoxic medications. Gadolinium-based contrast agents used in MRI pose a risk of nephrogenic systemic fibrosis primarily in G4 and G5 patients, but informing radiologists and ordering physicians of the G1 diagnosis ensures they use the lowest effective contrast dose and appropriate hydration protocols. Certain antibiotics — aminoglycosides (gentamicin, tobramycin), vancomycin, and amphotericin B — are nephrotoxic and require dose adjustment or avoidance in CKD patients at all stages. Any time a new medication is prescribed, informing the prescriber of the CKD diagnosis and the current eGFR allows them to check for dose adjustments.

Building Long-Term Habits at Stage 1

Stage G1 CKD is a long game. The interventions that matter most — blood pressure control, proteinuria reduction, glucose management, and lifestyle modifications — work through sustained adherence over months and years, not through acute treatment during a crisis. The patients who do best are those who internalize their diagnosis not as a source of alarm but as a set of conditions to monitor and manage consistently.

Practical habits that support long-term stability at Stage G1 include: keeping a record of annual eGFR and ACR results so trends are visible over time rather than having each result interpreted in isolation; maintaining a medication list that includes current eGFR and kidney disease status, shared with every prescriber including urgent care and emergency physicians; scheduling annual nephrology or primary care appointments proactively rather than waiting for symptoms to appear; and staying hydrated — dehydration acutely reduces GFR and is a preventable cause of eGFR dips in CKD patients at all stages. The annual monitoring framework that applies across all CKD stages is outlined in our guide to the annual kidney health checklist.

CKD is not a condition that responds to periodic bursts of effort — it responds to consistency. The encouraging reality at Stage G1 is that the most effective protective measures are precisely the ones most within a patient’s control: blood pressure management, medication adherence, avoiding nephrotoxic drugs, and lifestyle choices that reduce cardiovascular risk. None of these are passive — but all of them are achievable, and all of them make a measurable difference in long-term kidney function.

Sources: NIDDK — Chronic Kidney Disease | KDIGO CKD Guidelines 2024 | National Kidney Foundation | American Kidney Fund | Related: CKD Stages Explained | Kidney Function Tests | How Doctors Diagnose Kidney Disease | Questions to Ask at Your Checkup | Annual Kidney Health Checklist